COVID-19

Virex Pharma’s lead product is branded GlyXine^©  is being developed as an anti-viral treatment for respiratory infections including RSV and COVID-19.  The Food and Drug Administration (FDA) has provided a streamlined process to fast track new COVID-19 treatments called the Coronavirus Treatment Acceleration Program (CTAP).

The COVID-19 pandemic began in late 2019 with the virus evolving into a number of variants resulting in waves of infections around the globe. To date more than 6 million people worldwide are claimed to have lost their lives because of COVID-19 infection.  COVID-19 vaccines and oral anti-viral therapies are not readily available to most of the developing world which provides a reservoir for further evolution of viral variants.  This presents difficulties in developing an effective immunisation regimen. There is therefore a requirement for new anti-viral therapies which target all viral variants, that have a lower price point, can be used in non-clinical settings and are accessible to the populations in developing countries.